Weight | 1 lbs |
---|---|
Dimensions | 9 × 5 × 2 in |
host | mouse |
isotype | IgG |
clonality | monoclonal |
concentration | concentrate, predilute |
applications | IHC |
reactivity | human |
available size | 0.1 mL, 0.5 mL, 1 mL concentrated, 7 mL prediluted |
rabbit anti-PRAME monoclonal antibody (ZR383) 6345
$160.00 – $528.00
Antibody summary
- Rabbit monoclonal to PRAME
- Suitable for: Immunohistochemistry (formalin-fixed, paraffin-embedded tissues)
- Reacts with: Human
- Isotype:IgG
- Control: Testis or melanoma
- Visualization: Nucleus, cytoplasm, cell surface, chromosome, Golgi apparatus.
- 0.1, 0.5, 1.0 mL concentrated, 7 mL prediluted
rabbit anti-PRAME monoclonal antibody ZR383 6345
target relevance |
---|
Protein names Melanoma antigen preferentially expressed in tumors (Opa-interacting protein 4) (OIP-4) (Preferentially expressed antigen of melanoma) |
Protein family PRAME family |
Mass 57890Da |
Function Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation (PubMed:21822215, PubMed:26138980). The CRL2(PRAME) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding (PubMed:26138980). In the nucleus, the CRL2(PRAME) complex is recruited to epigenetically and transcriptionally active promoter regions bound by nuclear transcription factor Y (NFY) and probably plays a role in chromstin regulation (PubMed:21822215). Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG: prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis (PubMed:16179254). |
Pathway PATHWAY: Protein modification; protein ubiquitination. |
Subellular location Nucleus . Chromosome . Cytoplasm . Golgi apparatus . Cell membrane . Note=Associates with chromatin; specifically enriched at transcriptionally active promoters that are also bound by nuclear transcription factor Y (composed of NFYA, NFYB and NFYC) and at enhancers (PubMed:21822215). Recruited to the Golgi apparatus in response to interferon gamma (IFNG) treatment (PubMed:23460923). |
Tissues Expressed in testis. Detected in samples of kidney, brain and skin. |
Structure Component of a CRL2 E3 ubiquitin-protein ligase complex, also named ECS (Elongin BC-CUL2/5-SOCS-box protein) complex, composed of CUL2, Elongin BC (ELOB and ELOC), RBX1 and substrate-specific adapter PRAME (PubMed:21822215, PubMed:23460923, PubMed:26138980). Interacts with RARA (via the ligand-binding domain); the interaction is direct and ligand (retinoic acid)-dependent (PubMed:16179254). Interacts with EZH2; required to repress RAR signaling (PubMed:16179254). |
Target Relevance information above includes information from UniProt accession: P78395 |
The UniProt Consortium |
Data
![]() |
Formalin-fixed, paraffin-embedded human liver with metastatic melanoma stained with anti-PRAME antibody using peroxidase-conjugate and DAB chromogen. Note the nuclear staining in tumor cells |
Publications
Publications
pmid | title | authors | citation |
---|---|---|---|
We haven't added any publications to our database yet. |
Protocols
relevant to this product |
---|
IHC |
Documents
# | SDS | Certificate | |
---|---|---|---|
Please enter your product and batch number here to retrieve product datasheet, SDS, and QC information. |